The application concerns the design and use of small, duplex oligonucleotides and oligomers of nucleotide analogs. termed Chimeric Mutational Vectors (CMV) to effect muta tion in a target gene of a eukaryotic cell by homologous recombination between the CMV and the target. The CMV comprises ribonucleotides and deoxyribonucleotides and nucleotide analogs of each (generically "nucleobases"). The application discloses that CMV contain at least two seg ments of at least 3 ribo-type nucleobases paired to deoxyribo-type nucleobases, which regions flank the region of the CMV that corresponds to the mutation to be intro duced into the target gene. The ribo-type nucleobases should preferably be nuclease resistant i.e. other than naturally occurring ribonucleotides. The uses of CMV include gene therapy of genetic diseases and construction of transgenic plants and animals. The invention concerns compounds and methods of their use to make specific genetic alterations in the genome of target eukaryotic cells. More specifically, the invention concerns the introduction into the nucleus of the target cell of an oligonucleobase compound, termed a Chimeric Muta tional Vector (CMV), having a sequence that has regions of homology and one or more differences with a gene of the target cell that is to be altered (the "target gene"). The structure of the CMV is designed so that genetic recombi nation between the CMV and the target gene occurs, i.e., the sequence of the CMV replaces the sequence of the target gene.
BACKGROUND OF THE INVENTION
Site-Directed Genetic Alteration in Eukaryotic Cells Those skilled in the art of molecular biology recognize that on frequent occasions it is desired not merely to introduce a new polynucleic acid sequence, i.e. a new gene, into a targeted eukaryotic cell, but rather to alter a defined, pre-existing gene in the targeted cell. The targeted cell can be used in culture or it can be used to construct a transgenic animal.
A wide variety of techniques have been developed to introduce DNA into cultured eukaryotic cells. These tech niques include calcium phosphate precipitation and DEAE dextran mediated endocytosis, electroporation, liposome mediated fusion and transduction with replication incompe tent viruses. However, while such techniques can quite often introduce functional genes into the eukaryotic cell, these techniques do not readily accomplish an alteration (mutation) in a specific existing gene. After introduction the exogenous DNA is isolated at a randomposition in the cell's genome by illegitimate recombination, rather than at a specific position by homologous recombination.
Prior to the present invention, there was no generally satisfactory scheme for introducing a site-specific genetic alteration in a higher eukaryote, i.e., in mammalian or avian cells. Although homologous recombination can be obtained in higher eukaryotic cells by introduction of very long (>1 kb) nucleic acids, these techniques require the application of elaborate selection techniques because the rate of illegiti mate recombination in higher eukaryotes greatly exceeds that of homologous recombination. Thomas One approach to achieving a predominantly site-directed mutagenesis has been the introduction of single stranded oligodeoxynucleotides directly into the cell. This techniques has been successfully employed in the yeast Saccharomyces cerevisiae, in which homologous recombination is signifi cantly more active than it is in higher eukaryotes. Moerschell, R. P. et al., 1988, Proc. Natl. Acad, Sci. 85: 52428; Yamamoto, T., et al., 1992, Yeast 8: 935-48. However, to date there have been no reports of the success ful transformation of mammalian or avian cells by single stranded oligonucleotides.
A relationship between the structure of the target DNA and the rate of homologous recombination in mammalian can be inferred by studies that show that regions of alter The inclusion of a publication or patent application in this section is not to be understood as an admission that the publication or application occurred prior to the present invention or resulted from the conception of a person other than the inventor, An oligonucleotide having complementary deoxyribo nucleotides and ribonucleotides and containing a sequence homologous to a fragment of the bacteriophage M13mp19.
was described in Kmiec, E. B., et al., November 1994. Mol. and Cell. Biol. 14: 7163-7172 . The oligonucleotide had a single contiguous segment of ribonucleotides. Kmiec et al. showed that the oligonucleotide was a substrate for the REC2 homologous pairing enzyme from Ustilago maydis, Patent publication WO95/15972, published Jun. 15, 1995, and corresponding U.S. patent application Ser. No. 08/353,657, filed Dec. 9, 1994 , by E. B. Kmiec, described CMV for the introduction of genetic changes in eukaryotic cells. Examples in a Ustilago maydis gene and in the murine ras gene were reported. The latter example was designed to introduce a transforming mutation into the ras gene so that the successful mutation of the ras gene in NIH 3T3 cells would cause the growth of a colony of cells ("transformation"). The WO95/15972 publication reported that the maximum rate of transformation of NIH 3T3 was less than 0.1%, i.e., about 100 transformants per 10 cells exposed to the ras CMV. In the Ustilago maydis system the rate of transformants was about 600 per 10. A chimeric vector designed to introduce a mutation into a human bcl-2 gene was described in Kmiec, E. B., February 1996. Semi nars in Oncology 23: 188.
A CMV designed to repair the mutation in codon 12 of K-ras was described in Kmiec, E. B., December 1995, 5,731, 181 3 Advanced Drug Delivery Reviews 17: 333-40. The CMV was tested in Capan 2, a cell line derived from a human pancreatic adenocarcinoma, using LIPOFECTINTM to intro duce the CMV into a the Capan 2 cells. Twenty four hours after exposure to the CMV, the cells were harvested and genomic DNA was extracted; a fragment containing codon 12 of K-ras was amplified by PCR and the rate of conversion estimated by hybridization with allele specific probes. The rate of repair was reported to be approximately 18%.
A CMV designed to repair a mutation in the gene encod ing liver/bone/kidney type alkaline phosphatase was reported in Yoon, K., et al., March 1996 Nucleobases comprise a base, which is a purine, pyrimidine, or a derivative or analog thereof.
Nucleobases include peptide nucleobases, the subunits of peptide nucleic acids, and morpholine nucleobases as well An oligonucleobase strand generically includes both oli gonucleobase chains and segments or regions of oligo nucleobase chains. An oligonucleobase strand has a 3' end and a 5' end. When a oligonucleobase strand is coextensive with a chain, the 3' and 5' ends of the strand are also 3' and 5' termini of the chain.
A region is a portion of an oligonucleobase, the sequence of which is derived from some particular source, e.g., a CMV having a region of at least 15 nucleotides having the sequence of a fragment of the human B-globin gene. A segment is a portion of a CMV having some characteristic structural feature. A given segment or a given region can contain both 2'-deoxynucleotides and ribonucleotides. However, a ribo-type segment or a 2'-deoxyribo-type seg ment contain only ribo-type and 2'-deoxyribo-type nucleo bases respectively.
SUMMARY
The present invention provides oligonucleobase compounds, termed Chimeric Mutational Vectors (CMV). CMV can be used to introduce specific genetic changes in plant and animal cells. The invention is applicable to in the field of medicine for gene therapy, and in the fields of biomedical research, pharmaceutical production and agri culture to construct specifically mutated plants and animals. A CMV comprises two complementary oligonucleobase strands. The two strands can be present on a single chain or on two chains that can be optionally linked by any chemistry for cross-linking oligonucleotides.
The sequence of the strands of a CMV is homologous to the target gene except for a mutator region which introduces the genetic change into the target gene. The CMV can also contain regions having a sequence unrelated to the target gene. The mutator region must be directly adjacent in both 3' and 5' directions to a homology region of at least one base.
The oligonucleobases of the CMV are either ribo-type or 2'-deoxyribo-type. Ribo-type nucleobases contain a pentose furanosyl moiety having a 2 oxygen or halogen. At least three contiguous bases of the homologous region of the first strand are ribo-type nucleobases that are Watson-Crick base paired to deoxyribo-type nucleobases of the second strand. Nucleobases that are sensitive to RNase are not preferred for use in the invention.
DETALED DESCRIPTION OF THE INVENTION
The present invention provides compounds, termed Chi meric Mutational Vectors (CMV) that can be used to make 5,731, 181 S specific changes in the genome of a eukaryotic cell. The CMV are comprised of polymers of purines and pyrimidines that hybridize, i.e., form a Watson-Crick base pairs of purines and pyrimidines, to DNA having the appropriate sequence. Each CMV is divided into a first and a second strand of at least 15 bases each that are complementary to each other and can be, but need not be, covalently linked. The polymers of purines and pyrimidines. termed oligonucleobases, are comprised of two types of subunits. termed nucleobases. There are two types of nucleobases. Ribo-type nucleobases are ribonucleosides having a 2'hydroxyl, substituted hydroxyl or 2'halo-substituted ribose. All nucleobases other than ribo-type nucleobases are deoxyribo-type nucleobases.
The sequence of the first and second strands consists of at least two regions that are homologous to the target gene and one or more regions (the "mutator regions") that differ from the target gene and introduce the genetic change into the target gene. The mutator region is directly adjacent to homologous regions in both the 3' and 5' directions. In a preferred embodiment of the invention, each mutator region is adjacent in both the 3' and 5' directions to homologous regions of at least three bases. In a preferred embodiment of the invention, each mutator region is flanked in both the 3' and 5' directions by ribo-type oligonucleobase segments of at least three bases, which segments need not be adjacent to the mutator region. The flanking ribo-type nucleobase seg ments need not be directly adjacent to the mutator region, i.e., a portion of the homologous region comprising deoxyribo-type nucleobases can intervene. The total length of all homologous regions is preferably at least 14 bases. If the CMV contains two homologous regions separated by a mutator region, the homologous regions can more preferably be each between 8 and 12 bases long and most preferably be 10 bases long.
At least two homologous regions of the first strand are comprised of at least three contiguous ribo-type nucleobases which are Watson-Crick paired to deoxyribo-type nucleo bases of the second strand. In a preferred embodiment there are between 9 and 25 ribo-type nucleobases and more preferably 20 ribo-type nucleobases in the first strand, which are Watson-Crick paired to deoxyribo-type nucleobases of the second strand. In one embodiment there are no ribo-type nucleobases in the second strand. In one embodiment the mutator region of the first strand consists of deoxyribo-type nucleobases and is flanked by deoxyribo-type nucleobases. Alternatively, the mutator region can be comprised of ribo type nucleobases of the first strand and deoxyribo-type nucleobases of the second strand.
The CMV is still further characterized by containing at least three nuclease resistant ribo-type nucleobases. In a preferred embodiment all ribo-type nucleobases are nuclease resistant.
The mutator region can be as large as 2 kilobases and can encode an exon. Preferably the mutator region consists of 20 or fewer bases, more preferably 6 or fewer bases and most preferably 3 or fewer bases. The mutator region can be of a length different than the length of the sequence that separates the regions of the target gene homologous with the homolo gous regions of the CMV so that an insertion or deletion of the target gene results. When the CMV is used to introduce a deletion there is no base identifiable as within the mutator region. Rather, the mutation is effected by the juxtaposition of the two homologous regions that are separated in the target gene. In one embodiment the mutator region is a deletion of from 6 to 1 bases or more preferably from 3 to 1 bases. Multiple separated mutations can be introduced by In a preferred embodiment the CMV is resistant to RNase. Therefore, the use of only naturally occurring ribo-type nucleobases, which are sensitive to RNase, is not suitable for use in the invention. The ribo-type nucleobases of a CMV should include at least three ribo-type nucleobases prefer ably selected from non-phosphodiester linked ribonucle otides ("ribonucleotoids"). 2'O-substituted or 2'haloribonucleotides, 2 "O-substituted or 2haloribonucleotoids, and ribonucleosides, which can be optionally 2' substituted. In a preferred embodiment of the CMV, no nuclease sensitive, i.e., 2'O-ribonucleotides, are used.
In one embodiment the CMV is a single oligonucleobase chain of between 40 and 100 bases. In an alternative embodiment, the CMV comprises a first and a second oligonucleobase chain, each of between 20 and 100 bases; wherein the first chain comprises the first strand and the second chain comprises the second strand. The first and second chains can be linked covalently or, alternatively, can be associated only by Watson-Crick base pairings.
Uses of Chimeric Mutational Vectors
Chimeric Mutational Vectors can be used to introduce changes into the sequence any eukaryotic gene, which has a known sequence. The change can result in the replacement of one or more nucleotides or can be an insertion or deletion of one or more nucleotides. In preferred embodiments the replacement, insertion or deletion can be of 20 or fewer contiguous bases, in a more preferred embodiment the replacement, insertion or deletion can be of 6 or fewer bases and most preferably of 3 or fewer bases. The insertion can be as long as about two kilobases. The insertions or deletions can be made in the coding and the regulatory parts of the gene.
Cells can be transfected with the CMV by any technique now known or to be developed for transfecting cells with DNA. Such techniques include electroporation, liposome transfer and calcium phosphate precipitation. In one embodiment the transfection is performed with a liposomal transfer compound, e.g., DOTAP (N-1-(2,3-Dioleoyloxy) propyl)-N.N.N-trimethylammonium methylsulfate. Boehringer-Mannheim) or an equivalent, such as LIPOFEC TIN. The amount of CMV is not critical to the practice of the invention; good results can be achieved with 10 mM/10 cells. A ratio of about 500 ng of CMV in 3 ug of DOTAP per 10 cells can be used. The transfection technique of Examples 1-3, infra... can be used with the modification that the transfected cells are cultured in serum free media, media supplemented with human serum albumin or human serum.
The present invention encompasses methods of using
Chimeric Mutational Vectors. Uses of Chimeric Mutational
Vectors include the repair of genetic diseases such as Gau cher Disease, thalassemia and Sickle Cell disease. Other applications include the introduction of stop codons or frame shift mutations to make "knock-outs," i.e., transgenic ani mals or plants that lack a functional copy of a specific gene, as well as transgenic animals or plants having specific mutations. In a still further method of use encompassed by the invention specific mutations can be made for the purpose of studying the structure function relationships of genes-of interest. Alternatively, if a desirable mutation has been 5,731, 181 7 identified in one species, it can be introduced in the homolo gous genes of other species by use of the CMV.
For medical purposes, the invention can be used to repair mutations or introduce mutations into any cell-type that can be removed from a subject's body, cultured and reimplanted into the subject. Techniques for the removal, culture and reimplantation of hepatocytes, in particular of hepatic reserve (stem) cells, have been described in patent publica tion W094/08598 to Naughton, G. B. and Sibanda, B. Apr. 28, 1994 . Examples of genetic diseases that can be cured by repair of mutations in hepatocytes include: familial hypercholesteremia, caused by mutation in the LDL recep tor; emphysema that caused by a mutation in the Ol-antitrypsin gene; and hemophilia and Christmas Disease, which are caused by mutations in coagulation factors VIII and DX, respectively,
In a yet further use of the invention, CMV can be used to mutagenize a population of cells so that a mutant, having a selectable phenotype can be obtained. According to this aspect of the invention, a mixture of CMV having a mutator region of one or several nucleotides is synthesized so that the three non-wild type nucleotides are present at each position of the mutator region. The treatment of a population of cells with such a mixture of CMV will induce a variety of mutations in the target gene. After an appropriate selection step, a mutant having the desired phenotype can be recov ered. (d) and (e), which is complementary to a second strand con sisting of segment (a). In this particular embodiment the 3' terminus of the CMV is illustrated to be at the 3' end of the (a) segment and the 5' terminus is shown to be at the 5' end of the (h) segment. However, the location of the termini and the orientation of 3' and 5' directions of the CMV with respect to the segments can be elsewhere, so long as the termini do not interrupt the homologous or mutator regions of the first or second strands. The segments are labeled sequentially (a) through (h).
Structure of Exemplary Chimeric Mutational
In one embodiment the lengths and characteristics of the segments are as follows. Segment (a) is between 16 and 40 nucleotides and preferably between 20 and 30 nucleotides. The sequence of the region of segment (a) can be either that of the coding strand or the non-coding strand of the gene that contains the intended mutation (the "mutated target gene"). The location of the sequence of segment (a) must include the portion of the target gene that is to be changed. Unless the target gene is not normally transcribed in target cell, it is preferred that the sequence of segment (a) is the sequence of the coding strand of the target gene. When the target gene is not transcribed in the target cell, then neither the coding strand sequence or the non-coding strand sequence is pre The oligonucleobases of the portion of segment (a) that are base paired with segments (c) and (e) can be any 2'-deoxyribo-type nucleobases The nucleobase of segments (c) and (e), which are termed ribonucleotide segments, can be any ribo-type nucleobase 2' O-ribonucleotides, i.e., nucleotides that is known or will be developed. In a pre ferred embodiment, the nucleotides of segment (d), which is termed the intervening segment are 2'-deoxyribo-type nucleobases. Alternatively, segment (d) can be made of ribo-type nucleobases; in which case the boundaries between segments (c). (d) and (e) are not defined. Segments (b) and (f) through (h) can be of any type of nucleobase.
In a preferred embodiment, the sequence of segments (c) and (e) are completely homologous to the target gene. However, a one base mutator region in the (c) or (e) segment can result in the mutation of the target gene at the homolo gous position.
Segments (b) and (g) are about 4 nucleotides in length and form single stranded hairpin turns that allow segments (a) and (c)-(e) and segments (f) and (h) to form Watson-Crick base pairs, i.e., to form duplex nucleic acids. In alternative embodiments the function of segments (b) and (c), which is to covalently link the first and second strands, can be served by non-oligonucleobase moieties.
Segments (c) and (e), also termed the first and second ribo-type segments, consist, in one embodiment, of 2'-Omethylribonucleotides. In a preferred embodiment, seg ments (c) and (e) are independently, between 6 and 13 nucleotides.
Segment (d), also termed the intervening segment, in one embodiment, is between 4 and 20 nucleotides in length. If the target gene contains two or more point mutations that are separated by fewer than 15 nucleotides, each can be repaired by the same CMV.
Segments (f) and (h) form a duplex that brings the 3' and 5' ends of the CMV, which is nicked between segments (a) and (h) intojuxtaposition. The structure formed by segments (f), (g) and (h) is termed a hairpin cap. Ahairpin cap contains a terminal end and a nonterminal end. The terminal end forms a terminus of the chain, which can be either a 5' or a 3' terminus. The function of a hairpin cap is to control the position of the 3' or 5' terminus. The non-terminal end of the hairpin cap can be ligated to an end of a strand, whereby the end of the complementary strand, which is the second terminus of the chain is juxtaposed to the terminal end of the hairpin cap, as shown in FIG.1. The 3' and 5' terminican be, in one embodiment, dephosphorylated. In an alternative embodiment, the 3' and 5' termini can be covalently linked by a phosphodiester bond or equivalent, so that the CMV is a closed circular oligonucleotide. Segments (f) and (h) can be optionally deleted from a closed circular CMV. In a preferred embodiment the orientation of the oligonucleobase of the hairpin cap is the same as the orientation of the strand to which it is linked. If the orientation of the hairpin cap is anti-parallel to the orientation of the strand to which it is attached, the designation as 3' or 5' of the terminal end of the hairpin is determined by the structure of terminal end of the complementary.
In a preferred embodiment, the CMV is a single chain CMV containing one hairpin cap, oriented in parallel with the chain, having juxtaposed 3' and 5' ends. There are eight specific embodiments of this type, which are defined by the location of the ligation between the hairpin cap and the chain 5,731, 181 9 and by whether the sequence of the first strand is the sequence of the coding strand or the non-coding strand of the target gene. The eight species are given in Table I. FIG. 1  illustrates species 2 and 6 of Table I . Alternatively, the CMV can comprise two chains, each chain having a 3' and a 5' terminus, wherein a first chain comprises the first strand and a second chain comprises a An alternative embodiment of the two chain CMV can comprise two oligonucleobase chains and two hairpin caps; the first strand is a part of the first chain and the second strand is a part of the second chain. The hairpin caps can both be ligated to the ends of one strand. In one specific configuration, termed a "cradle' configuration, a hairpin cap is ligated to each end of the second strand. In an "anti cradle" configuration, the hairpin caps are ligated to the ends of the first strand. An alternative type of configuration. termed "head-to-tail." consists of a hairpin cap ligated to each of the strands. Because the strands of the CMV hybridize only in an antiparallel fashion, there are only two specific configurations of the head-to-tail type: the hairpin caps can both be ligated to either the 3' ends or the 5' ends of the strands.
The Synthesis of CMV and Selection of
Nucleobases CMV can be synthesized by any technique used to syn thesize oligonucleotides or oligonucleotide analogs. For CMV having chains up to about 100 bases in length, the preferred technique is solid-phase synthesis. Alternatively, subsegments of CMV chains greater than about 50 bases in length can be synthesized by solid phase synthesis and ligated by liquid phases techniques, well known to those skilled in the art. Wosnick, M.A., 1987, Gene 60: 115-117. As those skilled in the art appreciate, complementary sub segments can be synthesized by solid-phase techniques so that when annealed, the ends of the subsegments are stag gered. By causing adjacent subsegments to have comple mentary staggered ends, adjacent segments can be ligated by well known enzymatic processes. By this technique a chain of a CMV considerably larger than 100 bases can be synthesized. Those skilled in the art understand that PNA can hybridize to DNA in either orientation, i.e., either end of a PNA can be the 3' or 5' end. Peffer, N.J., et al., 1993, Proc. Natl. Acad.
Sci. 90: 10648-52. When a peptide nucleobase is present in an oligonucleobase strand having pentosefuranosyl containing nucleobases, the 3' and 5' ends of the strand are determined by the orientation of the pentosefuranosyl moi eties or, if none are present in the chain having the peptide nucleobase, then the 3' and 5' ends of the strand are deter mined by the orientation of pentosefuranosyl nucleobases of 5,731, 181 11 the complementary strand. Note, that the first strand of a CMV must contain at least three pentosefuranosyl nucleo bases.
EXAMPLES
Example 7.1. The Use of CMV to Repair Episomal Alkaline Phosphatase An expression plasmid containing the wild-type human liver/bone/kidney alkaline phosphatase cDNA under the control of the SV40 early promoter was obtained and designated pHAP. An identical plasmid with the mutant version of the cDNA was obtained and designated p711. The design of CMV to interconvert the sequences of pHAP and p711 are diagrammed in FIG. 2A . The CMVCh1 was designed to repair the missense mutation at position 711. It has a G residue, the wild-type sequence, at the site corre sponding to the mutation. Ch2 has a design identical to Chl except for an A instead of G at the site corresponding to position 711. Ch3 has the same sequence as Ch1 but the sequence of the ribonucleotide segments is that of the coding strand of the alkaline phosphate gene instead of the non coding strand. The oligonucleotide Dhl contained the same sequence as Chl, but contained only 2'-deoxynucleotides.
The schematic of p711 in FIG . 2B shows the single point mutation, A, at position 711 in the coding region of the alkaline phosphatase cDNA, the SV40 early promoter (P), SV40 origin of replication (ori), polyadenylation addition site and small-t intron sequence for splicing (SV40 poly A). The dotted box in FIG. 2B indicates the sequence from pBR322 encoding the origin of replication and 3-lactamase (Amp6) gene. CHO cells were transfected with p711 and 6 h later the CMV, Ch1, was introduced to CHO cells previ ously transfected with p711. Both transfections were per formed with lipofectin. The extent of the conversion to the wild-type phenotype was monitored at both biochemical and DNA sequence levels, by spectrophotometric measurement, histochemical staining and analysis of Hirt DNA.
Materials and Methods
Synthesis and purification of oligonucleotides: The chi meric oligonucleotides were synthesized on a 0.2 pmole scale using the 1000 A wide pore CPG on the ABI 394 DNA/RNA synthesizer. The exocyclic amine groups of DNA phosphoramidites (Applied Biosystems, Foster City, Calif.) are protected with benzoyl for adenine and cytidine and isobutyryl for guanine. The 2'-O-methyl RNA phos phoramidites (Glen Research. Sterling. Va.) are protected with phenoxyacetyl group for adenine, dimethylformami dine for guanine and isobutyryl for cytidine. After the synthesis was complete, the base-protecting groups were removed by heating in ethanol:concentrated ammonium hydroxide (1:3) for 20h at 55° C. The crude oligonucleotide sample was mixed with 7M urea and 10% glycerol, heated to 70° C. and loaded on a polyacrylamide gel containing 7M urea. After gel electrophoresis, DNA bands were visualized by UV shadowing. dissected from the gel, crushed and eluted overnight in TE buffer (10 mM Tris-HCl and 1 mM EDTA, pH 7.5) with shaking. The eluent containing gel pieces was spun through 0.45 m spin filter (Millipore, Bedford, Mass.) and precipitated with ethanol. Samples were further desalted by G-25 spin column (Boehringer Mannheim, Indianapolis, Ind.) and greater than 95% of the purified oligonucleotides were found to be full length. After 18 h, the medium was aspirated and 200 ul of DMEM containing 10% FBS was added to each well, The alkaline phosphate activity was measured 24 h after transfection of chimeric oligonucleotides. Spectrophotometric measure ment was carried out by the Elisa Amplification System (B.R.L. Bethesda, Md.). Cells were washed with 0.15M NaCl three times and lysed in 100 pil of NP40 buffer containing 10 mM NaCl, 0.5% NP40, 3 mM MgCl, and 10 mM Tris-HCl pH 7.5. A fraction of cell lysates (20 ul) was incubated with 50 ul of Elisa substrate and 50 ul of Elisa amplifier (B.R.L. Bethesda, Md.), the reaction was stopped by addition of 50 pil of 0.3MHSO, after 5 min of incubation with amplifier. The extent of reaction was carried out within the linear range of the detection method. The absorbance was read by an Elisa Plate Reader (B.R.L. Bethesda, Md.) at a wavelength of 490 nm.
Hirt DNA isolation, colony hybridization and direct DNA sequencing of PCR fragment: The cells were harvested for vector DNA isolation by a modified alkaline lysis procedure 24 h after transfection with the chimeric oligonucleotide. The cells were detached by trypsinization, washed, and resuspended in 100 pil of a solution containing 50 mM Tris-HCl pH 8.0, 10 mM EDTA and 110 ul of a solution containing 50 mM Tri-HCl pH 8.0, 10 mM EDTA and 100 pig?ml of RNase A. An equal volume of cell lysis solution (0.2N NaOH and 1% SDS) was added, followed by 100 ul of neutralization solution (3MKAc, pH 5.5). A 10-min room temperature incubation was followed by centrifugation of 10,000 rpm for 10 min. The supernatant was extracted with an equal volume of phenol-chloroform and precipitated with ethanol. Hirt DNA was transformed into E. coli DH.50 cells (B.R.L. Bethesda, Md.). Colonies from Hirt DNA were screened for specific hybridization for each probe designed to distinguish the point mutation. Colonies were grown on ampicillin plates, lifted onto nitrocellulose filter paper in duplicate, and processed for colony hybridization. The blots were hybridized to 'P-end-labelled oligonucleotide probes, 711-A (5'-CCGCCTACACCCACTCG-3' (SEQID NO: 1)) or 711-G (5'-CCGCCTACGCCCACTCG-3' (SEQ ID NO:
2)) at 37° C. in solution containing 5x Denhardts, 1% SDS, 2x SSC and 100 pg/ml denatured salmon sperm DNA. Blots were washed at 52 C. in TMAC solution (3.0M tetram ethylammonium chloride/50 mM Tris-HCl, pH 8.0.2 mM EDTA and 0.1% SDS). Plasmid DNA was made from twenty colonies shown to hybridize to either 711-G or 711-A, using the Qiagen miniprep kit (Chatworth, Calif.). Several hun Lysates were analyzed by 15% polyacrylamide gel contain-frequency of correction was measured by averaging the ing 7M urea followed by autoradiography. Oligonucleotides number of colonies hybridized to the 711-G or 711-A probe incubated in PMEM containing 10% FBS were processed sing more than 506 colonies hybridized to hido and analyzed in the same manner. 711-A probe using more than 500 colonies of the multiple In our experimental design, various chimeric oligonucle-plates generated from at least two separate transfection otides were introduced into CHO cells previously trans-experiments (Table I) . Similar frequencies of conversion fected with p711. The extent of the conversion to the 25 were observed for two batches of Ch1 prepared by separate wild-type phenotype was monitored by histochemical stain-synthesis. Approximately 70% of the colonies generated ing; red pigment was deposited on the cells expressing an from the Hirt DNA made from cells transfected with p711 active enzyme. When cells with he mutant gene were and Ch1 hybridized to the 711-A probe, while 30% of transfected with Ch1, red cells appeared at a frequency, of colonies exhibited hybridization to the 711-G probe (Table   approximately one in three transfected CHO cells, on the 30 I). Thus, a correction frequency of 30% was observed at 11 average, at 11 nM. In contrast, neither Ch2 nor Dh1 caused nM of Ch1, reproducibly. Hybridization was specific and no an increased enzymatic activity. Conversion to wild-type cross-hybridization was observed between the two popula was observed at a low level when cells were transfected with tions. DNA sequencing was carried out with plasmid DNAs
Ch3. The transfection frequency measured by the expression prepared from twenty of these colonies in both directions of the wild-type plasmid pHAP was estimated to be 30%. utilizing two primers (5-CAATGTCCCTGATGTTATGCA
The enzymatic activity was also measured by spectropho-3' (SEQID NO:5) and 5'-CGCTGGGCCAAGGACGCT-3' tometric method described above. A dose-dependent (SEQID NO: 6)), corresponding to position 630-650 and increase of alkaline phosphatase activity was observed up to 803-822 of the alkaline phosphatase cDNA flanking the 711 17 nM of Ch1 in the presence of p711 plasmid. The position. The sequence conversion was confirmed in each enzymatic activity of cells treated with Ch1 at 17 nM case and no other alteration in sequence was observed within approached 60% of that observed from cells transfected with several hundred of bases surrounding the target nucleotide. the wild-type plasmid, pHAP. The increase was sequence-All colonies from the Hirt extract prepared from Ch2 or specific since the same amount of Chl did not affect Dh1-treated cells hybridized to the 711-A probe only (Table  enzymatic activity of cells transfected with pHAP. I). Some colonies from the Hirt extract of the Ch3 hybrid Furthermore. Ch2 which contained a single base pair change 45 ized to the wild-type probe, but to a much lesser extent than from the Chi sequence did not cause any increase in that of the Chl (Table II) . These results confirmed that the enzymatic activity. The oligonucleotide, Dhl, which con-differential alkaline phosphatase activities exhibited were tained the same sequence as Ch1, but did not contain a due to the correction of the point mutation (A to G) at the ribonucleotide segment, did not exhibit an increase. Thus, DNA sequence level. RecA-deficient E. coli strains used to propagate plasmid DNA are capable of repair and homologous pairing func tions using episomal DNA. In order to rule out the possi bility that the sequence conversion is mediated by E. coli, direct DNA sequencing of a PCR-amplified fragment of Hirt DNA was carried out. Two primers flanking the 711 position were utilized to generate a 190 bp fragment through the action of Vent polymerase. The results indicated that posi tion 711 was a mixture of A(70%) and G(30%) when the Hirt DNA sample was made from the cells transfected cells with the combination of p711 and Chl. In contrast, no mixed sequence was observed at position 711 when Hirt DNA was made from oligonucleotide Dh1. These results established clearly that sequence correction by the chimeric oligonucle otide occurred in mammalian cells. Stability of chimeric oligonucleotide: The stability of the chimeric oligonucle otide was measured intracellularly and in growth medium containing 10% FBS. Ten nanogram of radiolabelled oligonucleotide, Ch1, was added to the same transfection experiment in which histochemical staining and Hirt DNA analyses was conducted (see Materials and Methods). The chimeric oligonucleotides are extremely stable. No detect able degradation was observed when chimeric oligonucle otide was incubated in growth medium containing 10% FBS, after 24 h incubation. Moreover, oligonucleotide iso lated from cells did not exhibit any degradation during the same incubation time. Only monomers of the chimeric oligonucleotide were detected when isolate from cells 24h after incubation. Thus, under the experimental conditions employed here, no end-to-end litigation of chimeric oligo nucleotides was observed. folded into the duplex conformation, one strand contained only DNA residues while the other strand contained the RNA/DNA blocks. In this case, the internal sequence is complementary to the B globin sequence over a stretch of 25 residues that span the site of the B mutation, with the exception of a single base (T) which is in bold and desig The CMV was introduced into the above-described lym phoblastoid cells homozygous for the is allele as follows.
Cells (1x10 per ml) were seeded in 1 ml of medium in each Shinsky and T. J. White, pp.146-152, Academic Press, (1990) .
Correction of the single base mutation was assessed by taking advantage of well known restriction fragment length polymorphisms resulting from the Bf mutation. R. F. Greeves et al., 1981, Proc. Natl. Acad. Sci. 78: 5081; J. C. Chang and Y. W. Kan, 1982, N. Eng. J. Med. 307:30; S. H. Orkin et al., ibid., p. 32; J.T. Wilson et al., 1982, Proc. Natl. DNA fragment of the 3-globin gene present normally is absent in the fallele and is replaced by a diagnostic 1.4 kbp fragment. When genomic DNA recovered from homozygous B lymphoblastoid cells was analyzed by this procedure, the expected 1.4 kbp fragment was observed. However, two fragments were observed in DNA from cells transfected with the SC1 CMV. The presence of the 1.2 kbp fragment in addition to the 1.4 kbp fragment indicates partial correction of the Ballele had taken place in a dose-dependent fashion.
To measure the efficiency of correction rapidly and sensitively, we adapted a PCR-based RFLP analysis. For the analysis of the B-globin sequence, the 345bp PCR fragment was prepared by amplification from a crude cell lysate using primers BG02 (5'-TCCTAAGCCAGTGCCAGAAGA-3' (SEQ ID NO: 7)) and B G 05 (5'-CTATTGGTCTCCTTAAACCTG-3' (SEQ ID NO: 8)) and Expand Taq polymerase (Boehringer Mannheim). For the analysis of the 3-globin gene, the same cell extracts were used in amplification reactions with primers DG06 (5'-CTCACAAACTAATGAAACCCTGC-3' (SEQID NO:9)) and DG07 (5'-GAAAACAGCCCAAGGGACAG-3 (SEQ ID NO: 10)) to generate a 335 bp fragment. Gels were stained with SYBRTM green (FMC Bioproducts) and fluo rescence intensities were quantitated using a Molecular Dynamics fluoroimager, DNA sequencing was performed in both directions using an ABI 373A sequencer.
The above primers were designed to yield a 345 bp fragment spanning the site of the is mutation after PCR amplification of genomic DNA. The fragment from normal cells contained a Bsu36 recognition sequence and yielded fragments of 228 bp and 117 bp, while DNA from is gene contained the sequence CCTGTGG and remained refractory to cutting. Analysis indicated that the 345bp DNA fragment amplified from SC1-treated is cells was partially cleaved with Bsu36I, indicating correction of the mutation on some, but not all, chromosomes. A quantitative measure was obtained by comparing the relative intensities of the three DNA fragments after electrophoretic separation and staining with the fluorescent dye SYBRTM green. The stained bands were imaged using a laser fluoroimager and the relative levels were calculated. Conversion efficiency was quanti tated by scanning the cyber green-stained agarose gel with a fluoroimager. Experiments at doses of between 2.5 and 25.0 pM of SC1/10 B lymphoblastoid cells showed between about 40% and 55% conversion of B to B (FIG.   4A ).
The frequency of introduction of the sickle mutation by the CMVSC2 was also determined by the methods set forth above. Analysis indicated that the level of correction exceeded 50% at the highest level of input chimeric molecule, 25 nM, but even at 2.5 nM correction of 30% of B-globin genes was observed (FIG. 4B) . were given G-CSF300 ug S.C. twice a day for five days. On the fourth and fifth days of G-CSF therapy they underwent a four hour stem cell apheresis using a COBE spectra pheresis machine. Mononuclear cells were prepared by density gradient centrifugation on Ficoll-Hypaque (density 1.077 g/ml, Pharmacia) (2000 rpm, 10 min, room temperature). The majority of the monocytes were removed after adherence to plastics (30 min, 37° C. in 5% CO in RPMI with 10% FBS). Cells were harvested by swirling to remove cells loosely adherent to the plastics which were washed 3 times with PBS. This population was incubated with biotinylated murine anti-CD34 antibodies in PBS/1% BSA for 25 min at room temperature at a concentration of 100x10 cells/ml. The antibody-treated cells were passed over an avidin column and those passing through the column were then collected for analysis. Subsequently the column was washed with PBS and CD34" cells adhering to the column were recovered by squeezing the column. Synthesis and purification of oligonucleotides: The chi meric oligonucleotides were synthesized on a 0.2 umole scale using the 1000 A wide pore CPG on the ABI 394 DNA/RNA synthesizer. In this construct, the exocyclic amine groups of DNA phosphoramidites (Applied Biosystems) are protected with benzoyl for adenine and cytidine and isobutyryl for guanine. The 2'-O-methyl RNA phosphoramidites (Glen Research, Sterling, Va.) are pro tected with phenoxyacetyl group for adenine. dimethylfor mamidine for guanine and isobutyryl for cytidine. After synthesis, the base-protecting groups were removed by heating in ethanol: concentrated ammonium hydroxide (1:3) for 20h at 55° C. The crude oligonucleotides were purified by polyacrylamide gel electrophoresis and the sample was mixed with 7M urea and 10% glycerol, heated to 70° C. and loaded on a 10% polyacrylamide gel containing 7M urea. After gel electrophoresis. DNA bands were visualized by UV shadowing. dissected from the gel. crushed and eluted overnight in TE buffer (10 mM Tris-HCl and 1 mM EDTA, pH 7.5) with shaking. The eluent containing gel pieces was spun through 0.45um spin filter (Millipore, Bedford, Mass.) and precipitated with ethanol. Samples were further desalted by G-25 spin column (Boehringer Mannheim) and greater than 95% of the purified oligonucleotides were found to be full length. RESULTS: The isolated CD34"-enriched population was utilized first in an oligonucleotide uptake experiment. The chimeric molecule SC2 was mixed with the liposome for mulation DOTAP under the conditions described above except that a radioactive tag was placed at the 5' end of the oligonucleotide. Increasing amounts of labeled and unla beled oligonucleotide were incubated with the liposome for 15 minutes. The mixture was then incubated with cells for 6 hours after which the cells were washed extensively with PBS to reduce nonspecific binding. The cells were then centrifuged and the pellet fraction was washed with 0.2M glycine (pH 4.5) to eliminate any remaining nonspecific binding. The radioactivity in the cell pellet was determined by scintillation counting. The chimeric oligonucleotide was absorbed by the cell in dose-dependent fashion. Since our experimental strategy focused on nanomolar concentrations, we did not extend the curve beyond 25 nM. Based on the Genomic DNA from B cells that had been treated with SC2 was PCR-amplified utilizing the two B-globin specific primers, PCOs and PCO,. Only wild-type B-globin sequence was found, which confirmed that the SC2 CMV is B-globin specific. 8. The compound of claim 5, which further comprises a region having a sequence of at least 14 contiguous nucleo bases or a pair of regions having sequences of at least 7 contiguous nucleobases wherein each said sequence is the sequence of a fragment of a mammalian gene or of its complement.
9. The compound of claim 5, which further comprises a region having a sequence of at least 14 contiguous nucleo bases or a pair of regions having sequences of at least 7 nucleobases wherein each said sequence is the sequence of a fragment of a plant gene or of its complement.
10. The compound of claim 5, in which the first strand comprises at least 9 ribo-type nucleobases.
11. The compound of claim 5, in which the second strand contains no ribo-type nucleobases.
12. The compound of claim 5, which contains no peptide nucleobases.
13. The compound of claim 12, which comprises only pentosefuranosyl nucleobases.
14. The compound of claim 13, which comprises one oligonucleobase chain.
15. The compound of claim 14, which further comprises: a) a hairpin cap attached to the first strand or the second strand; and b) a linker having a first end and a second end, which first end is covalently attached the 3' end of the first strand and which second end is covalently attached to the 5' end of the second strand. 18. The compound of claim 14, which further comprises: a) a hairpin cap attached to the first strand or the second strand; and b) a linker having a first and a second end, which first end is covalently attached the 5' end of the first strand and which second end is covalently attached to the 3' end of the second strand.
19. The compound of claim 18, in which the 3' end of the first strand is the 3' terminus.
20. The compound of claim 18, in which the 5' end of the second strand is the 5' terminus.
21. The compound of claim 5. in which the first strand comprises a first ribo-segment consisting of at least 6 ribo-type nucleobases, a second ribo-segment consisting of at least 3 ribo-type nucleobases, and an intervening deoxyribo-segment consisting of at least 42'-deoxyribo-type nucleobases.
22. The compound of claim 5, in which the first strand comprises a nuclease resistant ribo-type nucleobase other than a 2'OMe-ribonucleotide.
23. The compound of claim 5, in which the second strand comprises a 2'-deoxyribo-type nucleoside or a peptide nucleobase.
24. A method of isolating a cell having an alteration in a target sequence of the genome of the cell, which alteration causes a selectable phenotypic change of the cell, which comprises the steps of: a) providing the oligonucleobase of claim 1, which further comprises two regions homologous with a target sequence and a mutator region, disposed there between, encoding the alteration; b) maintaining said oligonucleobase within the nucleus of 
